Rigel to Present at Cowen and Company 36th Annual Health Care Conference

Feb 29, 2016, 07:30 ET from Rigel Pharmaceuticals, Inc.

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Monday, March 7th at 2:40 p.m. ET.

To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com) Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN).  In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Ryan Maynard Phone: 650.624.1284 Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Rivily, Inc. Phone: 650.430.3777 Email: susan@rivily.com

Logo - http://photos.prnewswire.com/prnh/20030226/RIGLLOGO

 

SOURCE Rigel Pharmaceuticals, Inc.



RELATED LINKS

http://www.rigel.com